Ionis Pharmaceuticals
IONS
Market cap $6.8B

41.82 USD

-0.87

2.04%

At close Aug 25, 4:00 PM EDT

After hours

41.83

+0.01

0.02%

1 day

-2.04%

5 days

-3.84%

1 month

-1.02%

3 months

25.51%

6 months

31.30%

Year to date

20.55%

1 year

-10.64%

5 years

-20.95%

10 years

-9.97%

About: Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Employees: 927

Healthcare Biotechnology

0

Funds holding %

of 7,429 funds

0

Analysts bullish %

of 11 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 6 [Q1] → 12 (+6) [Q2]

84% more call options, than puts

Call options by funds: $48.1M | Put options by funds: $26.1M

42% more first-time investments, than exits

New positions opened: 81 | Existing positions closed: 57

33% more capital invested

Capital invested by funds: $5.01B [Q1] → $6.67B (+$1.67B) [Q2]

12% more repeat investments, than reductions

Existing positions increased: 120 | Existing positions reduced: 107

5% more funds holding

Funds holding: 339 [Q1] → 357 (+18) [Q2]

1.72% more ownership

Funds ownership: 104.33% [Q1] → 106.05% (+1.72%) [Q2]

See Fund Rankings

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$46

10%

upside

Avg. target

$62

49%

upside

High target

$82

96%

upside

11 analyst ratings

9 positive

82%

2 neutral

18%

0 negative

0%

JP Morgan Jessica Fye	17%upside $49	Neutral Maintained	25 Aug 2025
Needham Joseph Stringer	32%upside $55	Buy Reiterated	25 Aug 2025
Citigroup David Lebowitz	65%upside $69	Buy Maintained	22 Aug 2025
Piper Sandler Allison Bratzel	55%upside $65	Overweight Maintained	22 Aug 2025
Barclays Gena Wang	39%upside $58	Overweight Maintained	22 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 9 articles about IONS published over the past 30 days

US FDA approves Ionis' drug for rare genetic disorder

The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe swelling in various parts of the body of patients with a rare genetic disorder.

US FDA approves Ionis' drug for rare genetic disorder

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. DAWNZERA is the first and only RNA-targeted medicine approved for HAE, designed to target plasma prekallikrein (PKK), a key protein that activates inflammatory mediators associated with acute a.

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

The Motley Fool

Ionis (IONS) Q2 Revenue Soars 101%

Ionis Pharmaceuticals (IONS -0.44%), a biotechnology company focused on RNA-targeted therapeutics, reported its second quarter 2025 earnings on July 30, 2025. The headline news was a substantial beat on both GAAP revenue and non-GAAP earnings compared to Wall Street estimates.

Ionis (IONS) Q2 Revenue Soars 101%

Zacks Investment Research

Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook

Ionis crushes Q2 estimates with EPS of $0.86 and sales of $452 million, lifting its 2025 revenue forecast and sending shares up 5%.

Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook

Ionis Pharmaceuticals, Inc. (IONS) Q2 2025 Earnings Call Transcript

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q2 2025 Earnings Conference Call July 30, 2025 11:30 AM ET Company Participants Brett P. Monia - Founder, CEO & Director D.

Ionis Pharmaceuticals, Inc. (IONS) Q2 2025 Earnings Call Transcript

Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug

Ionis Pharmaceuticals Inc. IONS reported second-quarter adjusted earnings of 85 cents on Wednesday. The company reported an adjusted loss of $35 million a year ago.

Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug

Zacks Investment Research

Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings

While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings

Zacks Investment Research

Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates

Ionis Pharmaceuticals (IONS) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to a loss of $0.45 per share a year ago.

Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates

Ionis reports second quarter 2025 financial results and highlights progress on key programs

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2025. “During the second quarter, we continued to build momentum across our business,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “Our strong performance included excellent commercial execution, resulting in a substantial increase in TRYNGOLZA revenues, our first independently launched med.

Ionis reports second quarter 2025 financial results and highlights progress on key programs

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion of TRYNGOLZA® (olezarsen) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS). The positive opinion is now referred to the European Commission (EC) for an approval decision, which is expected by Q4.

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)

See News Rankings

Charts implemented using Lightweight Charts™